To address these limitations a multi-disciplinary team created a panel of in vitro assay systems (representing meningioma and schwannoma, merlin wildtype and merlin-deficient, and human and murine cells) to perform traditional drug screening studies in a systematic fashion with an initial set of drugs chosen for their potential relevance to NF2 biology. The gene discussed is NF2; the disease is meningioma.